Barclays analyst Ramsey El-Assal maintains Paychex (NASDAQ:PAYX) with a Equal-Weight and raises the price target from $106 to $115.
Gilead’s Kite Announced Tecartus Car T-cell Therapy Showed Durability of Response, With Median Overall Survival Not Yet Reached Among Patients Who Achieved a Complete Response in Data Presented at ASCO
Kite, a Gilead Company (NASDAQ: GILD), today announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel).
